PCSK9
Proprotein convertase subtilisin/kexin type 9
The protein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene located on human chromosome 1. It is the ninth member of the protein convertase family, a group of enzymes that can activate homologous genes found in many species[1]. PCSK9 is a liver-synthesized protease that plays a major role in regulating the levels of low-density lipoprotein receptors (LDLR) on the surface of liver cells and can inhibit the LDLR recycling pathway. PCSK9 binds to LDLR on the surface of liver cells, escorts LDLR to lysosomes for degradation, and prevents LDLR from recirculating to the cell membrane, effectively increasing the level of circulating LDL. Therefore, inhibiting the activity of the PCSK9 protease can down-regulate circulating LDL levels. PCSK9 is closely associated with various cardiovascular diseases, especially hypercholesterolemia and atherosclerosis[2].
All Product Categories
-
PCSK9 Related Products (96)
Related Products (96)
-
Dim16
0 ImagesCat. No.: HY-149310CAS No.: 2743448-32-8Dim16 is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 can be used in research related to hypercholesterolemia.
-
PCSK9-IN-18
0 ImagesCat. No.: HY-153454CAS No.: 2455425-15-5PCSK9-IN-18 (compound 188) is a potent PCSK9 inhibitor with a KD value of <200 nM.
-
Bezeparsen sodium scrambled negative control
0 ImagesCat. No.: HY-147252CBezeparsen sodium scrambled negative control is the sequence scrambled negative control of Bezeparsen sodium.
-
PCSK9-IN-22
0 ImagesCat. No.: HY-160036CAS No.: 2794203-47-5
-
PCSK9-IN-26
0 ImagesCat. No.: HY-161434CAS No.: 3033361-09-7PCSK9-IN-26 (Compound 116) is an PCSK9 inhibitor (IC50 < 1 nM). PCSK9-IN-26 can be used for metabolic research.
-
PCSK9-IN-31
0 ImagesCat. No.: HY-161942CAS No.: 2247649-76-7PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats.
-
PCSK9 autophagic degrader 2
0 ImagesCat. No.: HY-176043CAS No.: 2974497-11-3
-
PCSK9-IN-14
0 ImagesCat. No.: HY-153391CAS No.: 2913198-84-0PCSK9-IN-14 (compound Ia-8) is a potent PCSK9 inhibitor.
-
Inclisiran sodium scrambled negative control
0 ImagesCat. No.: HY-132591CInclisiran sodium scrambled negative control is the sequence scrambled negative control of Inclisiran sodium.
-
PCSK9-IN-17
0 ImagesCat. No.: HY-153453CAS No.: 2455424-72-1PCSK9-IN-17 is a PCSK9 inhibitor. PCSK9-IN-17 can be used for the research of cholesterol metabolism (WO2020150474A1, compound 105).
-
ALD306
0 ImagesCat. No.: HY-P991343Synonyms: ALD309ALD306 is a human monoclonal antibody (mAb) targeting PCSK9. ALD306 can be used in Hypercholesterolaemia research.
-
Lerodalcibep
0 ImagesCat. No.: HY-P99696CAS No.: 2250073-78-8Synonyms: LIB003Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases.
-
PCSK9-IN-24
0 ImagesCat. No.: HY-163141CAS No.: 2974496-96-1
-
PCSK9 modulator-4
0 ImagesCat. No.: HY-146085CAS No.: 2476490-20-5PCSK9 modulator-4 (Compound 21) is a potent modulator of PCSK9 with an EC50 value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia.
-
PCSK9 Inhibitor, EGF-A
0 ImagesCat. No.: HY-P11071PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor with LDLR degradation inhibitory activity and LDLR recycling promoting activity. PCSK9 Inhibitor, EGF-A is a synthetic peptide consisting of 42 amino acid residues, which contains the calcium-binding site of the epidermal growth factor A domain (EGF-A). PCSK9 Inhibitor, EGF-A reduces plasma LDL cholesterol levels by maintaining hepatic LDLR levels and enhancing the clearance capacity of circulating LDL. PCSK9 Inhibitor, EGF-A can be used in research related to hypercholesterolemia, premature atherosclerosis, coronary heart disease and familial hypercholesterolemia.
-
PCSK9-IN-15
0 ImagesCat. No.: HY-153451CAS No.: 2455423-94-4PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, KD <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia.
-
MeIm
0 ImagesCat. No.: HY-161941CAS No.: 2043947-71-1
